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Hyponatremia is associated with elevated wait-list mortality among end-stage liver disease candidates for liver transplanta-
tion (LT). However, the effect of low serum sodium on the survival benefit of LT has not been examined. We sought to deter-
mine whether pretransplant hyponatremia is associated with an altered LT survival benefit. Data were obtained from the
Scientific Registry of Transplant Recipients. The study population consisted of adults (age 18 years) placed on the waiting
list for LT between January 1, 2005 and December 31, 2012 (n569,213). The effect of hyponatremia on the survival benefit
was assessed via sequential stratification, an extension of Cox regression. Each transplant recipient was matched to appro-
priate candidates then active on the waiting list with the same Model for End-Stage Liver Disease (MELD) score and in the
same donation service area. The focus of the analysis was the interaction between the serum sodium and the MELD score
with respect to the survival benefit of LT; this was defined as the covariate-adjusted hazard ratio contrasting post-LT mortal-
ity and pre-LT mortality. The LT survival benefit increased significantly with decreasing serum sodium values when the
MELD scores were >11. The survival benefit of LT was not affected by serum sodium for patients with MELD scores 11.
In conclusion, the LT survival benefit (or lack thereof) is independent of serum sodium for patients with MELD scores11.
The increase in the survival benefit with decreasing serum sodium among patients with MELD scores> 11 is consistent
with recently approved changes to the allocation system incorporating serum sodium. Liver Transpl 21:308-313, 2015.
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The existing liver allocation policy is based on
waiting-list urgency.1 The Model for End-Stage Liver
Disease (MELD) score, a metric of wait-list mortality,
has served as an allocation tool for candidates with
chronic liver disease awaiting liver transplantation
(LT) in the United States since 2002.2,3 The MELD
score, calculated with serum bilirubin, serum creati-
nine, and the international normalized ratio of the
prothrombin time,3,4 is used to rank-order candidates
with end-stage liver disease on the waiting list.5
LT provides a large differential between waiting-list
mortality risk and posttransplant mortality risk. Stud-
ies by Merion et al.6 demonstrated a MELD score below
which candidates did not receive a significant survival
benefit from LT because of higher 1-year post-LT mor-
tality versus 1-year wait-list mortality.6 On the basis of
these findings, the board of directors of the Organ Pro-
curement and Transplantation Network approved the
Share 15 modification to the deceased donor organ
allocation policy in the United States. The revised policy
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increased access to deceased donor organs for candi-
dates with MELD scores of 15 or higher by offering
organs regionally to candidates above the threshold
before local candidates under the threshold.5,6
Studies have shown that low serum sodium at LT is
associated with higher waiting-list mortality among
LT candidates.7-9 Kim et al.8 noted that the effect of
hyponatremia on waiting-list mortality gradually
diminishes as the MELD score increases, and they
concluded that adding serum sodium to the MELD
score could reduce waiting-list mortality by as much
as 7%. However, the effect of serum sodium on the
survival benefit of LT is largely unknown. Data from
single-center studies regarding short- and long-term
mortality after LT among patients with low serum
sodium levels before transplantation are conflict-
ing.10,11 In a quite recent study of 19,537 patients,
Leise et al.12 showed no difference in 90-day post-LT
mortality between patients with serum sodium lev-
els<131 mmol/L and patients with serum sodium
levels between 131 and 145 mmol/L.12
Because serum sodium is associated with wait-list
mortality, the board of directors of the Organ Procure-
ment and Transplantation Network recently approved
the addition of compensatory points for serum sodium
to the MELD score in order to increase access to LT
for patients with lower MELD scores and hyponatre-
mia. Once implemented, this policy will provide 1 to
13 additional points to the MELD score according to
the serum sodium value. For example, a candidate
with a MELD score of 12 and a serum sodium level of
125 mmol/L would get 11 additional points for a new
MELD score of 23.13 Although the addition of serum
sodium to the allocation algorithm may reduce
waiting-list mortality by providing enhanced access to
donor organs to candidates with low serum sodium
levels, it is not known whether any or all candidates
with low serum sodium levels would gain an incre-
mental survival benefit over those with normal serum
sodium levels. Therefore, this study examined the
effect of serum sodium on the survival benefit of LT.
PATIENTS AND METHODS
Data Source and Study Population
This study used data obtained from the Scientific Regis-
try of Transplant Recipients (SRTR). The SRTR main-
tains a database of all candidates for and recipients of
solid organ transplants in the Untied States on the basis
of data submitted bymembers of theOrganProcurement
and Transplantation Network. The SRTR supplements
data collected by transplant programs with mortality
information from theSocial SecurityDeathMaster File.
Broadly, eligible LT candidates with chronic liver dis-
ease are ranked by descending MELD score within a
blood type. The MELD score is computed with serum
creatinine, serum bilirubin, and the international nor-
malized ratio of the prothrombin time, and it is updated
periodically.14 Complete details of MELD-based
deceased donor liver allocation are publicly available.14
The study population included adults with an initial
date of registration on the deceased donor LT waiting
list between January 1, 2005 and December 31, 2012
(n569,213). Mandatory submission of serum sodium
to the Organ Procurement and Transplantation Net-
work at initial candidate registration and with MELD
updates was in effect before the starting date of the
cohort. Candidates listed as status 1 for acute liver
failure were excluded. Candidates were censored upon
the receipt of a living donor transplant. Patients were
followed from the date of wait listing to the earliest of
death, the receipt of a living donor transplant, or the
end of the observation period on December 31, 2012.
This study was approved by the University of Michigan
Institutional Review Board.
Statistical Analysis
For descriptive analyses, continuous variables were
summarized as means and standard deviations; cate-
gorical variables were described as category-specific
counts and proportions.
The survival benefit of LT was estimated with
sequential stratification,15-17 an established extension
of Cox regression for evaluating time-dependent treat-
ments, such as transplantation, in the presence of
time-dependent patient characteristics, such as the
MELD score and serum sodium. A separate stratum
was created for each recipient of a deceased donor
transplant. Transplants to status 1 patients or
patients with a MELD exception score were excluded.
Each stratum included the transplant recipient as
well as a set of matched candidates; specifically, these
were candidates who were in active status on the
waiting list and had spent the same previous time on
the waiting list, had the same MELD score, and were
listed in the same organ procurement organization
donation service area.
In agreement with our exclusion criteria for LT
recipients, in setting up the matched sets (ie, compar-
ator wait-list candidates), we excluded candidates
who were status 1 or had received a MELD exception
before the time of the index candidate’s transplant.
For each candidate in the stratum, the covariate vec-
tor was defined on the basis of the candidate’s status
at the time of inclusion in the stratum. The model
was adjusted for age, sex, race/ethnicity, diagnosis,
body mass index, blood type, albumin, dialysis, diabe-
tes, ascites, hepatic encephalopathy, and hospitaliza-
tion status. Standard errors and P values were based
on a robust (sandwich) variance estimator that
accounted for the repetition of patients across strata.
The missingness for age, sex, race/ethnicity, ascites,
hepatic encephalopathy, MELD components, and
serum sodium was 0%. Height and weight were miss-
ing for 0.5% and 0.2%, respectively, and hospitaliza-
tion status was missing for 6% of the recipients.
Missingness of this magnitude could not realistically
have any meaningful impact on the analysis, particu-
larly because the most important predictors were
essentially never missing.
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The LT survival benefit was defined as the
covariate-adjusted hazard ratio (HR) corresponding to
an LT (0, 1) indicator; specifically, the HR represents
the post-LT death rate divided by the waiting-list (pre-
LT) death rate, with all adjustment covariates and
stratification factors (the latter being the basis of the
matching) equal.6 If the HR is greater than 1.0, then
posttransplant mortality is greater than mortality on
the waiting list, and this implies that no survival ben-
efit is received. Conversely, if the HR is less than 1.0,
then posttransplant mortality is lower than mortality
on the waiting list, and a survival benefit is conferred.
When the HR equals 1.0, posttransplant mortality
and waiting-list mortality are equal.
Since the relationship between the MELD score and
the LT survival benefit is now well described in the liter-
ature,6,16,18 we focused on quantifying the degree to
which the LT survival benefit depends on serum
sodium, that is, the degree to which the HR contrasting
post- and pre-LT mortality changes with serum sodium.
Within each MELD category, we coded this interaction
as the product between the LT indicator and serum
sodium. Through this approach, the HR represents the
change (per unit change in serum sodium) in the HR
and contrasting post- and pre-LT mortality.
All statistical analyses were conducted with SAS 9.3
(SAS Institute, Cary, NC).
RESULTS
Table 1 summarizes the characteristics of the cohort.
The mean serum sodium levels at the time of wait list-
ing and transplantation were 136 and 135 mmol/L,
respectively. Figure 1A shows the distribution of serum
sodium at the time of wait listing, whereas Fig. 1B
presents the analogous distribution of serum sodium
at the time of LT. As shown by the descriptive statis-
tics, the centers of the distributions are very similar.
The distribution of serum sodium at listing is nega-
tively skewed in comparison with serum sodium at LT.
Waiting List and Posttransplant Events
There were 69,213 patients in the study population,
and deceased donor LT was performed 23,446 times
during the study period. There were 14,249 waiting-
list deaths and 5107 posttransplant deaths.
Effect of Sodium on Survival Benefit by MELD
Category
Our primary interest was the interaction between the
survival benefit of LT and serum sodium. Because it
TABLE 1. Baseline Characteristics of the Cohort at Listing and at LT
At Listing (n569,213) At LT (n523,446)
Age (years)* 54.1 (9.6) 53.0 (9.7)
Males [n (%)] 45,666 (66) 15,687 (67)
Hepatitis C [n (%)] 25,927 (37) 8568 (37)
Cholestatic cirrhosis [n (%)] 5038 (7) 2126 (9)
Noncholestatic cirrhosis [n (%)] 25,270 (37) 10,188 (43)
Caucasian race [n (%)] 49,167 (71) 17,100 (73)
MELD score* 16.7 (8.1) 25.3 (8.4)
Serum sodium (mmol/L)* 136 (4.8) 135 (5.4)
Serum creatinine (mg/dL)* 1.3 (1.2) 1.8 (1.5)
Serum bilirubin (mg/dL)* 4.9 (7.6) 10.8 (11.9)
International normalized ratio* 1.6 (0.7) 2.1 (1.2)
Renal replacement therapy [n (%)] 2658 (3.8) 3593 (15)
Albumin (g/dL)* 3.1 (0.7) 2.9 (0.7)
*The data are presented as means (with standard deviations in parentheses).
Figure 1. Distribution of serum sodium (A) at listing and (B) at
LT.
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is now well known that the survival benefit of LT
depends strongly on the MELD score,6,16,18 the evalua-
tion of the sodium-LT interaction was within MELD
categories. We chose 6 to 8, 9 to 11, 12 to 14, 15 to 17,
18 to 19, 20 to 29, 30 to 39, and 40 as the MELD
groupings; this was consistent with many previously
published analyses.6,16,18 The initial models estimated
separate serum sodium–LT survival benefit interac-
tions, with similar adjacent categories combined.
Results based on the final interaction model are dis-
played in Tables 2 and 3 and Fig. 2A,B; that is, all
results are based on the same model. In Table 2, the
sodium-LT interaction effects are presented by MELD
category. The interaction is significant for MELD
scores>11 but nonsignificant for MELD scores of 6 to
11 (P50.81). Because of the directionality (1 versus –),
the survival benefit of LT diminishes significantly
(ie, HR approaches 1, which indicates equality between
post- and pre-LT mortality) as serum sodium increases.
If we consider the HR for LT with a MELD score in the
20 to 29 category, a model without the interaction with
serum sodium assumes that this HR is equal across all
sodium levels. However, for the survival benefit that
corresponds to this MELD score range (20-29), each 5-
U decrease in serum sodium is associated with a
25.3% decrease in the LT HR (ie, an increased LT sur-
vival benefit as serum sodium decreases).
A somewhat different perspective of the results is
provided by Table 3. For each MELD category, we list
the HR for LT corresponding to a serum sodium level
of 135 mmol/L. Note that the interaction model
assumes that the “within MELD score” survival bene-
fit of LT depends on serum sodium; such an LT HR
cannot be calculated without the prespecification of a
sodium value.
We chose 135 mmol/L because this value is close to
the mean and median for both the wait-list and LT
populations. Consider 2 different patients with a
MELD score of 16. The first patient has a sodium level
of 135 mmol/L, so the survival benefit of LT is
described as HR50.29 (representing a 71% mortality
reduction). In contrast, the second patient has a
sodium level of 130 mmol/L; the lower sodium level
puts patient 2 at a higher risk of pre-LT mortality in
comparison with patient 1, and as a result, the LT
survival benefit is represented as HR50.25 (repre-
senting a 75% mortality reduction). Taking the ratio
of these 2 HRs yields the HR multipliers listed in
Table 2 since these two middle columns in Table 3
contrast 2 patients with equal MELD scores whose
serum sodium values differ by 5 U. For example, as
shown in the last column of Table 3, 0.29/0.25
equals 1.145, which equals the 14.5% increase in the
HR listed in Table 2. In Fig. 2A,B, we plot LT survival
benefit HRs by serum sodium. In each panel, the
slope represents the per-unit change in the LT sur-
vival benefit HR. We plotted the results for the 5th,
25th, 50th, 75th, and 95th percentiles of the distribu-
tion of serum sodium at LT. The discrepancy in the
TABLE 2. Effect of Serum Sodium on the LT Survival
Benefit (Interaction Between LT and Sodium by the
MELD Category)
MELD
Category
Change in HR per 5-Units
Increase in Serum Sodium P Value
6-11 22.7% 0.81
12-19 114.5% 0.001
20-29 125.3% <0.001
30-40 133.7% <0.001
TABLE 3. Application of the Interaction Model at
Different Serum Sodium Levels by the MELD Category
MELD
Category
HR (Sodium5
135 mmol/L)
HR (Sodium5
130 mmol/L) HR
6-8 2.06 2.11 0.973
9-11 0.71 0.73 0.973
12-14 0.43 0.37 1.145*
15-17 0.29 0.25 1.145*
18-19 0.25 0.22 1.145*
20-29 0.23 0.18 1.253*
30-39 0.15 0.11 1.337*
40 0.12 0.09 1.337*
*The ratio is significantly (P<0.05) different from 1
(which represents a significant interaction).
Figure 2. Effect of serum sodium on the survival benefit of LT
with MELD scores of (A) 6 to 11 and (B) 12 to 40.
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slopes for the nonsignificant (Fig. 2A) and significant
MELD groups (Fig. 2B) is considerable.
DISCUSSION
This is the first study to examine the relationship
between serum sodium and the survival benefit of LT.
Our results showed that a decrease in serum sodium
was associated with a significantly enhanced survival
benefit only for those with MELD scores>11. At
MELD scores11, serum sodium did not affect the
survival benefit. These findings are novel in expanding
the scope of prior studies that focused on the effect of
hyponatremia on waiting-list mortality alone, and
they thus may have important implications for patient
counseling, organ acceptance decision making, and
allocation policy development.
Although hyponatremia is a common problem in
patients with advanced cirrhosis,19,20 the level of
serum sodium used to confer that descriptor is not
standardized. Hyponatremia in patients with decom-
pensated cirrhosis has been defined in older studies as
a serum sodium level<130 mmol/L, even though the
lower limit of normal serum sodium concentrations is
135 mmol/L.20 Furthermore, the prevalence of
patients with cirrhosis with abnormal serum sodium
levels between 131 and 135 mmol/L was 27% in a
large population study.19 Such patients showed patho-
genic and clinical features similar to those of patients
with serum sodium levels lower than 130 mmol/L.20
Biggins et al.7 showed that serum sodium was a sig-
nificant predictor of waiting-list mortality on the basis
of multicenter data, and they incorporated serum
sodium into a modified MELD equation. Kim et al.8
further developed this concept with SRTR data. Both
of these studies provided an evidence base for the
incorporation of serum sodium into the MELD score.
Kim et al. showed that the effect of serum sodium on
waiting-list mortality was more pronounced at lower
MELD scores. Our study showed that the patients
with the lowest MELD scores (MELD scores of 6-8)
had significant harm from transplantation, regardless
of the serum sodium level. Serum sodium did not
influence the survival benefit for patients with MELD
scores of 9 to 11. Serum sodium modulated the sur-
vival benefit for patients with MELD scores>11.
There is precedent for changes to the medical
urgency–based liver allocation system based on obser-
vations regarding survival benefit. For example, the
Share 15 rule (allocating liver allografts to candidates
in a larger geographic area with MELD scores15
ahead of local candidates with MELD scores<15) was
implemented on the basis of data available at the time
showing that those with MELD scores<15 did not
receive a significant transplant survival benefit.21
There have been other iterative changes in national
liver allocation policy over the past several years
designed to increasingly direct donor livers to those
with higher MELD scores; most recently, geographic
barriers to organ access have been removed for
patients with MELD scores35.5,22 Kim et al.8 pre-
dicted that a proposed sodium-modified MELD score,
predicated exclusively on estimates of waiting-list mor-
tality, would result in very little change in the alloca-
tion ranking of wait-listed candidates with MELD
scores>30. However, our study found that among
patients undergoing transplantation with MELD scores
of 30 to 40, every 5-U decrease in serum sodium was
associated with a 33.7% increase in survival benefit.
Thus, consideration of waiting-list mortality alone fails
to account for the added survival advantage for candi-
dates near the top of the MELD-ordered waiting list
who have hyponatremia. These candidates should be
of interest to policymakers interested in making
adjustments to the current allocation system.
In a recent prospective study in one region of the
United States, 90% of those granted MELD exception
scores for low serum sodium underwent transplanta-
tion within 3 months, whereas 49% of nonexception
candidates did.23 Prioritizing all hyponatremic
patients without an accompanying minimum MELD
score is likely to have unintended consequences; at
worst, it may increase the transplant rates of patients
with low MELD scores (6-11) who may not receive a
significant survival benefit, and at best, it may direct
donor organs to those with less survival benefit in
comparison with those with higher laboratory-based
MELD scores and normal serum sodium levels. Our
study excluded MELD exception patients.
This study has some limitations. The observational
study design may have resulted in bias due to patient
selection and unmeasured patient characteristics. How-
ever, the prospective mandatory collection of serum
sodium by the Organ Transplant and Procurement Net-
work in the absence of any allocation-based incentives
made it possible to analyze the association of serum
sodium with waiting-list mortality as well as posttrans-
plant mortality in the calculation of the survival benefit
in an unbiased ecology. Although large observational
studies derived from administrative and clinical data-
bases have proven very useful for health services
research, the accuracy of these databases in terms of
data quality and completeness is often questioned. The
missingness in our cohort was very minimal.
In conclusion, our results suggest that the incorpora-
tion of adjustments to the MELD score based on serum
sodium for the purpose of liver allocation should be
considered for candidates with a baseline MELD score
of at least 12. Deliberation regarding the precise level of
MELD above which additional points for hyponatremia
should be applied should occur before the adoption
and implementation of a modified allocation system. In
the meantime, caregivers should counsel patients on
the LT waiting list that there are consequences of hypo-
natremia with respect to the likelihood of death on the
waiting list and the expected survival benefit of LT.
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